Detalhe da pesquisa
1.
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Lancet
; 392(10162): 2378-2387, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30360970
2.
Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries.
Ann Rheum Dis
; 78(11): 1472-1479, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31427438
3.
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.
J Drugs Dermatol
; 15(5): 568-80, 2016 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27168266
4.
The development of systemic sclerosis classification criteria.
Clin Rheumatol
; 26(9): 1401-9, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17285223
5.
Translation and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI) for use in Ukraine.
Clin Rheumatol
; 30(10): 1305-10, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21494807
6.
A proposal of criteria for the classification of systemic sclerosis.
Med Sci Monit
; 10(11): CR615-21, 2004 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-15507853